Cochrane · systematic review · CD001949
Pimozide for schizophrenia or related psychoses
Mothi, M, Sampson, S · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
32
current version
GRADE rated
15
No studies
15
Included studies
NR
No studies 15 · 46.9%Ungraded 2 · 6.3%Very low 7 · 21.9%Low 7 · 21.9%Moderate 1 · 3.1%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
PIMOZIDE versus PLACEBO for schizophrenia or related psychoses
Population: patients with schizophrenia or related psychoses
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: relapse medium term (3‐12 months) Clinical diagnoses PIMOZIDE vs PLACEBO | RR 0.22 [0.03, 1.78] | 1 study · 20 participants | Very low Downgraded: imprecision, indirectness |
Mental state: no improvement medium term (3‐12 months) not reported PIMOZIDE vs PLACEBO | no estimate extracted | NR | No studies |
Mental state: specific symptoms first‐rank symptoms medium term (3‐12 months) not reported PIMOZIDE vs PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal adverse effects: Parkinsonism (rigidity) short term (<3 months) Clinical diagnoses PIMOZIDE vs PLACEBO | RR 5.5 [0.3, 101.28] | 1 study · 19 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects: extrapyramidal adverse effects:Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses PIMOZIDE vs PLACEBO | RR 1.33 [0.14, 12.82] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects: extrapyramidal adverse effects:Parkinsonism (tremor) medium term (3‐12 months) Clinical diagnoses PIMOZIDE vs PLACEBO | RR 1 [0.2, 4.95] | 1 study · 25 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported PIMOZIDE vs PLACEBO | no estimate extracted | NR | No studies |
PIMOZIDE versus ANY ANTIPSYCHOTIC for schizophrenia or related psychoses
Population: patients with schizophrenia or related psychoses
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: relapse medium term (3‐12 months) Clinical diagnoses PIMOZIDE vs ANY ANTIPSYCHOTIC | RR 0.82 [0.57, 1.17] | 7 studies · 227 participants | Moderate Downgraded: imprecision |
Mental state: no improvement medium term (3‐12 months) As defined in each study PIMOZIDE vs ANY ANTIPSYCHOTIC | RR 1.09 [0.08, 15.41] | 1 study · 23 participants | Very low Downgraded: risk of bias, imprecision |
Mental state: presence of first‐rank symptoms medium term (3‐12 months) Clinical diagnoses PIMOZIDE vs ANY ANTIPSYCHOTIC | RR 0.53 [0.25, 1.11] | 1 study · 44 participants | Low Downgraded: imprecision |
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses PIMOZIDE vs ANY ANTIPSYCHOTIC | RR 1.25 [0.37, 4.17] | 6 studies · 186 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses PIMOZIDE vs ANY ANTIPSYCHOTIC | no estimate extracted | 5 studies · 219 participants | Low Downgraded: imprecision |
Adverse effects: extrapyramidal adverse effects Parkinsonism (tremor) medium term (< 3 months) Clinical diagnoses PIMOZIDE vs ANY ANTIPSYCHOTIC | RR 1.45 [0.68, 3.09] | 4 studies · 175 participants | Low Downgraded: risk of bias, imprecision |
Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported PIMOZIDE vs ANY ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
PIMOZIDE + ANY ANTIPSYCHOTIC versus ANY ANTIPSYCHOTIC for schizophrenia or related psychoses
Population: patients with schizophrenia or related psychoses
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: relapsemedium term (3‐12 months) Clinical diagnoses PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC | RR 0.28 [0.15, 0.5] | 1 study · 69 participants | Low Downgraded: risk of bias |
Mental state: no improvementmedium term (3‐12 months)not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
Mental state: presence of first‐rank symptoms medium term (3‐12 months)not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal adverse effects Parkinsonismshort term (< 3 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal adverse effects Parkinsonismmedium term (3‐12 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
Quality of life: average change score medium term (3‐12 months) Specific Level of Functioning, SLOF (high = better, skewed) PIMOZIDE + ANY ANTIPSYCHOTIC vs ANY ANTIPSYCHOTIC | no estimate extracted | 1 study · 53 participants | Ungraded |
PIMOZIDE + ANY ANTIPSYCHOTIC versus ANTIPSYCHOTIC + PLACEBO for schizophrenia or related psychoses
Population: patients with schizophrenia or related psychoses
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: relapse medium term (3‐12 months) PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO | RR 0.64 [0.37, 1.1] | 4 studies · 507 participants | Ungraded |
Mental state: no improvement medium term (3‐12 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO | no estimate extracted | NR | No studies |
Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal adverse effects Parkinsonism short term (< 3 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal adverse effects Parkinsonism medium term (3‐12 months) Extrapyramidal Symptom Rating Scale (ESRS) PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO | no estimate extracted | 1 study · 53 participants | Low Downgraded: imprecision |
Quality of life: average change score medium term (3‐12 months) Specific Level of Functioning scale (SLOF) PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO | no estimate extracted | 1 study · 53 participants | Low Downgraded: imprecision |
PIMOZIDE + ANY ANTIPSYCHOTIC versus ANTIPSYCHOTIC + ANTIPSYCHOTIC for schizophrenia or related psychoses
Population: patients with schizophrenia or related psychoses
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Global state: relapse medium term (3‐12 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
Mental state: no improvement medium term (3‐12 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC | no estimate extracted | NR | No studies |
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Adverse effects: extrapyramidal adverse effects Parkinsonism (tremor) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC | no estimate extracted | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life: average change score medium term (3‐12 months) not reported PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + ANTIPSYCHOTIC | no estimate extracted | NR | No studies |